Lento Bio

Lento Bio is pioneering a disease-modifying therapeutic approach for presbyopia, the universal age-related loss of near vision affecting over 1.8 billion people. Its lead candidate, LB-01, is a small molecule prodrug eye drop designed to cleave disulfide crosslinks in the lens, restoring flexibility and accommodation. The company is in the discovery/IND-enabling stage, with compelling preclinical data showing significant rejuvenation of lens flexibility in models. Lento Bio operates in a massive, underserved market with no approved disease-modifying treatments, positioning it as a potential disruptor in ophthalmology and aging biology.

Small molecule prodrug platform designed to reverse molecular damage (specifically disulfide crosslinks) in aging, non-regenerative tissues. Focus on compounds that mimic/enhance endogenous protective pathways (e.g., glutathione) with improved tissue penetration and target engagement, delivered via topical eye drops.

Competition includes approved symptomatic treatments like miotic eye drops (e.g., AbbVie's Vuity) and a range of surgical/optical corrections. Lento's approach is distinct as a potential disease-modifying therapy, but it faces competition from other biotechs exploring novel mechanisms for presbyopia reversal, all aiming to capture share in the large existing vision correction market.